ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

PRTC Puretech Health Plc

222.50
-2.50 (-1.11%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Puretech Health Plc LSE:PRTC London Ordinary Share GB00BY2Z0H74 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.50 -1.11% 222.50 223.50 225.00 227.00 222.00 226.00 158,894 16:35:03
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Home Health Care Services 23.75M -50.35M -0.1839 -12.10 609.35M

PureTech Health PLC Results of Annual General Meeting (6343O)

18/05/2018 4:45pm

UK Regulatory


Puretech Health (LSE:PRTC)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Puretech Health Charts.

TIDMPRTC

RNS Number : 6343O

PureTech Health PLC

18 May 2018

18 May 2018

PureTech Health plc

Results of Annual General Meeting

The Annual General Meeting of PureTech Health plc (LSE: PRTC) ("PureTech Health" or the "Company"), was held at 3.00 pm BST on Friday 18 May 2018. All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll.

The results of the poll, incorporating the proxy votes lodged in advance of the meeting, are set out below. All resolutions were passed by greater than 90% of the shares voted at the meeting.

 
       Resolutions             For          %       Against       %     Withheld      Total 
                                                                                      votes 
                                                                                       cast 
------------------------  ------------  --------  -----------  ------  ---------  ------------ 
 001. To approve 
  the Company's 
  Annual Report 
  and Accounts 
  for year end 
  31 December 
  2017                     210,722,410   100.00%     7,634      0.00%      0       210,730,044 
------------------------  ------------  --------  -----------  ------  ---------  ------------ 
 002. To approve 
  the Directors' 
  Remuneration 
  Report                   209,827,359   99.57%     902,586     0.43%     100      210,729,945 
------------------------  ------------  --------  -----------  ------  ---------  ------------ 
 003. To elect 
  Mr. Joichi 
  Ito as a director        210,624,785   99.95%     105,260     0.05%      0       210,730,045 
------------------------  ------------  --------  -----------  ------  ---------  ------------ 
 004. To elect 
  Dr. Raju Kucherlapati 
  as a director            210,730,045   100.00%       0        0.00%      0       210,730,045 
------------------------  ------------  --------  -----------  ------  ---------  ------------ 
 005. To elect 
  Dr. John LaMattina 
  as a director            210,730,045   100.00%       0        0.00%      0       210,730,045 
------------------------  ------------  --------  -----------  ------  ---------  ------------ 
 006. To elect 
  Dame Marjorie 
  Scardino as 
  a director               210,722,410   100.00%     7,634      0.00%      0       210,730,044 
------------------------  ------------  --------  -----------  ------  ---------  ------------ 
 007. To elect 
  Mr. Christopher 
  Viehbacher 
  as a director            210,730,045   100.00%       0        0.00%      0       210,730,045 
------------------------  ------------  --------  -----------  ------  ---------  ------------ 
 008. To elect 
  Dr. Robert 
  Langer as 
  a director               204,282,162   96.94%    6,447,882    3.06%      0       210,730,044 
------------------------  ------------  --------  -----------  ------  ---------  ------------ 
 009. To elect 
  Dr. Bennett 
  Shapiro as 
  a director               200,079,010   95.02%    10,478,827   4.98%   172,207    210,557,837 
------------------------  ------------  --------  -----------  ------  ---------  ------------ 
 010. To elect 
  Ms. Daphne 
  Zohar as a 
  director                 210,730,045   100.00%       0        0.00%      0       210,730,045 
------------------------  ------------  --------  -----------  ------  ---------  ------------ 
 011. To elect 
  Mr. Stephen 
  Muniz as a 
  director                 210,624,785   99.95%     105,260     0.05%      0       210,730,045 
------------------------  ------------  --------  -----------  ------  ---------  ------------ 
 012. To reappoint 
  KPMG LLP as 
  Auditors of 
  the Company              210,730,045   100.00%       0        0.00%      0       210,730,045 
------------------------  ------------  --------  -----------  ------  ---------  ------------ 
 013. To authorise 
  the Board 
  of Directors 
  to determine 
  the Auditors' 
  remuneration             210,730,045   100.00%       0        0.00%      0       210,730,045 
------------------------  ------------  --------  -----------  ------  ---------  ------------ 
 014. To authorise 
  the allotment 
  of shares                193,151,796   91.66%    17,578,249   8.34%      0       210,730,045 
------------------------  ------------  --------  -----------  ------  ---------  ------------ 
 015. To dis-apply 
  pre-emption 
  rights                   207,997,472   98.70%    2,732,572    1.30%      0       210,730,044 
------------------------  ------------  --------  -----------  ------  ---------  ------------ 
 016. To further 
  dis-apply 
  pre-emption 
  rights for 
  acquisitions 
  and specified 
  capital investments.     205,997,704   97.75%    4,732,340    2.25%      0       210,730,044 
------------------------  ------------  --------  -----------  ------  ---------  ------------ 
 017. To authorise 
  market purchase 
  of own shares            210,728,861   100.00%     1,184      0.00%      0       210,730,045 
------------------------  ------------  --------  -----------  ------  ---------  ------------ 
 018. To authorise 
  general meetings 
  to be called 
  on not less 
  than 14 clear 
  days' notice             210,276,172   99.78%     453,873     0.22%      0       210,730,045 
------------------------  ------------  --------  -----------  ------  ---------  ------------ 
 

Due to its shareholding in the Company, Invesco Asset Management Limited is deemed to be a controlling shareholder as defined in the Financial Conduct Authority's Listing Rules. Accordingly, each resolution to elect an independent director (resolutions 4, 5, 6 and 7) has under Listing Rule 9.2.2E been approved by a majority of the votes cast by:

   --     the shareholders of the Company as a whole; and 

-- the independent shareholders of the Company, that is, all the shareholders entitled to vote on each resolution excluding the controlling shareholder as shown below.

 
       Resolutions             For          %      Against     %     Withheld      Total 
                                                                                   votes 
                                                                                    cast 
------------------------  ------------  --------  --------  ------  ---------  ------------ 
 004. To elect 
  Dr. Raju Kucherlapati 
  as a director            120,568,048   100.00%      0      0.00%      0       120,568,048 
------------------------  ------------  --------  --------  ------  ---------  ------------ 
 005. To elect 
  Dr. John LaMattina 
  as a director            120,568,048   100.00%      0      0.00%      0       120,568,048 
------------------------  ------------  --------  --------  ------  ---------  ------------ 
 006. To elect 
  Dame Marjorie 
  Scardino as 
  a director               120,560,413   99.99%     7,634    0.01%      0       120,568,047 
------------------------  ------------  --------  --------  ------  ---------  ------------ 
 007. To elect 
  Mr. Christopher 
  Viehbacher 
  as a director            120,568,048   100.00%      0      0.00%      0       120,568,048 
------------------------  ------------  --------  --------  ------  ---------  ------------ 
 

Notes:

(1) A vote "Withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

(2) As at 17 May 2018, the number of issued shares in the Company was 282,429,696 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

(3) The full text of the resolutions may be found in the Notice of the Annual General Meeting, copies of which are available on both the Company's website www.puretechhealth.com/ and on the National Storage Mechanism.

(4) In accordance with Listing Rule 9.6.2, a copy of the resolutions, other than those concerning ordinary business has been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.morningstar.co.uk/uk/NSM.

(5) With respect to resolution 17 and as further explained in the explanatory notes in the circular sent to shareholders of the Company on 16 April 2018, Invesco Asset Management Limited (acting as agent for and on behalf of its discretionary managed clients) does not have a nominee director on the board of directors of the Company and is therefore, in the view of the Company, not treated as acting in concert with any of the directors for the purposes of Note 1 of Rule 37.1 of the City Code on Takeovers and Mergers ("Rule 37.1") which provides an exception to the obligation to make a mandatory offer in consequence of a company's purchase of its own shares under Rule 37.1. In accordance with Note 4 of Rule 37.1, the Company will consult the Panel on Takeovers and Mergers in advance of any implementation of a purchase of its own shares pursuant to the authority granted by this resolution.

About PureTech Health

PureTech Health (PRTC.L) is an advanced, clinical-stage biopharmaceutical company developing novel medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems (brain-immune-gut or the "BIG" axis), which together represent the adaptive human systems. PureTech Health is at the forefront of understanding and addressing the biological crosstalk associated with the BIG axis. By harnessing this emerging field of biology, PureTech Health is pioneering new categories of medicine with the potential to have great impact on people with serious diseases. PureTech Health is advancing a rich pipeline of innovative therapies that includes two pivotal stage programmes, multiple human proof-of-concept studies and a number of early clinical and pre-clinical programmes. PureTech's research and development pipeline has been advanced in collaboration with some of the world's leading scientific experts, who along with PureTech's team of biopharma pioneers, entrepreneurs and seasoned Board, identify, invent and clinically de-risk new medicines. With this experienced team pursuing cutting-edge science, PureTech Health is building the biopharma company of the future focusing on improving and extending the lives of people with serious disease. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to PureTech's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither PureTech Health nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

 
        Investors                     EU media 
   Allison Mead Talbot        Ben Atwell, Rob Winder 
     +1 617 651 3156            +44 (0) 20 3727 1000 
  amt@puretechhealth.com    ben.atwell@FTIconsulting.com 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGFKFDQPBKDNPD

(END) Dow Jones Newswires

May 18, 2018 11:45 ET (15:45 GMT)

1 Year Puretech Health Chart

1 Year Puretech Health Chart

1 Month Puretech Health Chart

1 Month Puretech Health Chart

Your Recent History

Delayed Upgrade Clock